10-K: Applied Therapeutics 2023 10-K Filing: Progress in Rare Disease and Diabetic Complications

Applied Therapeutics' 2023 10-K filing highlights advancements in their pipeline, including regulatory submissions for AT-007 and positive trial results for AT-001.

Summary

• Applied Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for rare metabolic diseases and diabetic complications.
• Their lead candidate, AT-007 (govorestat), is being developed for Galactosemia, SORD Deficiency and PMM2-CDG.
• A Marketing Authorization Application (MAA) for AT-007 in Galactosemia was submitted to the European Medicines Agency (EMA) and accepted for review in December 2023.
• A New Drug Application (NDA) for AT-007 in Galactosemia was submitted to the US FDA in December 2023 and granted Priority Review with a PDUFA target action date of August 28, 2024.
• Phase 3 trial data for AT-007 in SORD Deficiency showed a 52% reduction in sorbitol levels after 90 days and a statistically significant correlation between sorbitol level and clinical endpoints after 12 months.
• AT-001 (caficrestat) for diabetic cardiomyopathy (DbCM) showed a trend in stabilizing cardiac function in a Phase 3 trial, with a statistically significant improvement in a pre-specified subgroup not on SGLT2 or GLP-1 therapies.
• The company discontinued its early-stage preclinical PI3K program and returned the rights to AT-104 to Columbia University.
• Applied Therapeutics reported a net loss of $119.8 million for the year ended December 31, 2023, and had an accumulated deficit of $468.6 million.
• As of December 31, 2023, the company had cash and cash equivalents of $49.9 million.
• The company has raised additional capital through an ATM agreement, warrant exercises and a private placement in early 2024, bringing cash and cash equivalents to $153.5 million as of March 1, 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there are positive developments in the pipeline and regulatory submissions, the company is still incurring significant losses and faces challenges in clinical trials. The recent capital raise is a positive sign, but the overall sentiment is cautiously optimistic.

Positives

• Regulatory submissions for AT-007 in Galactosemia are progressing in both the US and Europe.
• Phase 3 trial results for AT-007 in SORD Deficiency are positive, showing significant biomarker and clinical improvements.
• AT-001 showed a positive trend in stabilizing cardiac function in DbCM patients, with a statistically significant benefit in a specific subgroup.
• The partnership with Advanz Pharma provides a clear path for commercialization of AT-007 in Europe and potential revenue.
• The company has secured additional funding, extending its cash runway into 2026.

Negatives

• The company has incurred significant operating losses and has an accumulated deficit of $468.6 million.
• The Phase 3 trial for AT-001 in DbCM did not meet its primary endpoint in the overall population.
• The company discontinued its early-stage preclinical PI3K program.
• The company is dependent on third-party manufacturers for its product candidates.
• The company has a limited operating history and has not yet generated any product revenue.

Risks

• The company's success is dependent on the successful clinical development, regulatory approval, and commercialization of its product candidates.
• Clinical trials are expensive, time-consuming, and subject to factors outside the company's control.
• The company's product candidates may cause undesirable side effects, affecting regulatory approval and commercial potential.
• The company may face substantial competition from other pharmaceutical and biotechnology companies.
• The company is subject to healthcare laws and regulations, which carry substantial penalties for noncompliance.
• The company relies on third parties to conduct preclinical studies, clinical trials, and produce supplies of its product candidates.
• The company may be subject to intellectual property claims and may not be able to protect its intellectual property rights.
• The company is dependent on key personnel and may experience difficulties in managing growth.
• The company may be affected by unfavorable research or reports and may use its cash and cash equivalents ineffectively.

Future Outlook

The company expects to continue to incur significant expenses and increasing operating losses for the foreseeable future. They plan to leverage abbreviated development programs and biomarker-based approaches for rapid drug development and regulatory approval where possible. For indications that require standard development programs, they plan to seek strategic partnerships.

Management Comments

• Our management team and scientific advisory board are composed of accomplished scientists and clinicians with decades of experience developing drugs for a wide range of diseases.
• Our view is that drug development does not always need to follow the standard approach, which often requires long and costly development programs before drugs become available to patients.
• By taking a unique and focused approach to drug development, we believe we can significantly shorten development programs and bring lifesaving drugs to patients in urgent need.

Industry Context

The company is operating in a competitive biopharmaceutical industry with rapidly advancing technologies. They are targeting areas with high unmet medical needs, such as rare diseases and diabetic complications, where there is a significant opportunity for new therapies. The company is also leveraging expedited regulatory pathways to accelerate drug development.

Comparison to Industry Standards

• The company's approach of targeting validated molecular pathways with improved drugs is similar to other companies in the biopharmaceutical industry, but their focus on specific enzyme inhibitors and tissue permeability profiles is a differentiating factor.
• The company's use of biomarkers to confirm biological activity is consistent with industry best practices for de-risking clinical development.
• The company's reliance on third-party contract manufacturing organizations (CMOs) is a common practice in the industry, especially for smaller companies.
• The company's financial results, including net losses and accumulated deficit, are typical for a clinical-stage biopharmaceutical company that has not yet generated product revenue.
• The company's cash runway into 2026 is a positive sign, but they will need to continue to raise capital to fund their operations and development programs.

Management Changes

Related Party Transactions

• The company made payments to Alexandria LaunchLabs, a subsidiary of Alexandria Real Estate Equities, Inc., where a member of the company's board of directors is the founder and executive chairman.

Stakeholder Impact

• Shareholders may experience volatility in the stock price due to the company's financial performance and the inherent risks of drug development.
• Employees may benefit from the company's growth and potential success in bringing new therapies to market.
• Patients with rare metabolic diseases and diabetic complications may benefit from the company's development of new treatments.
• Customers (potential partners and healthcare providers) may benefit from the company's product candidates if they receive regulatory approval and are commercialized.
• Suppliers and creditors may benefit from the company's continued operations and potential growth.

Next Steps

• The company plans to meet with regulatory agencies to discuss the interim analysis of the Phase 3 INSPIRE trial for AT-007 in SORD Deficiency.
• The company plans to initiate a clinical development program on AT-007 in PMM2-CDG.
• The company plans to explore the safety, tolerability, PK profile and biomarker effects of AT-003 in a Phase 1a/1b clinical trial in diabetic patients.
• The company plans to continue to pursue additional opportunities for financing and business development.

Key Dates

Keywords

Aldose Reductase Inhibitor, Galactosemia, SORD Deficiency, Diabetic Cardiomyopathy, AT-007, AT-001, Clinical Trials, Regulatory Approval, Rare Diseases, Biopharmaceutical, Drug Development